Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks

Core Insights - Emergent BioSolutions has received FDA approval for new multipack configurations of NARCAN Nasal Spray, expanding its product offerings to include 6-count and 24-count options, aimed at enhancing distribution efficiency and cost-effectiveness [1][2] Product Development - The new multipack formats are designed to meet the needs of partners distributing higher volumes of naloxone, thereby improving accessibility for community programs and organizations involved in large-scale distribution efforts [1][2] - This approval follows the recent FDA approval of the NARCAN Nasal Spray Carrying Case in January 2026, indicating Emergent's ongoing commitment to enhancing the accessibility and usability of NARCAN [2] Market Impact - Since its prescription launch in 2016, over 85 million doses of NARCAN Nasal Spray have been distributed across the U.S. and Canada, highlighting the product's significant market presence and impact in combating opioid overdose [2]